|
AL101 mediated tumor inhibition in notch-altered TNBC PDX models. |
|
|
Research Funding - Ayala Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
|
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
|
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
|
|
Employment - Champions Oncology |
Stock and Other Ownership Interests - Champions Oncology |
|
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
|
|
Consulting or Advisory Role - Ayala Pharmaceuticals; InSilico Medicine; Y-Trap Inc. |
|
|
Honoraria - Cell Signaling Technologies |
Consulting or Advisory Role - Ayala Pharmaceuticals; Cellestia Biotech; Epizyme |
Patents, Royalties, Other Intellectual Property - Brigham and Women's Hospital |
|
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Ayala Pharmaceuticals |
Travel, Accommodations, Expenses - Ayala Pharmaceuticals |